Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
urothelial bladder cancer
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "urothelial bladder cancer" in MCE Product Catalog:
Cat. No.: HY-159642
CAS No.: 2800223-30-5
Synonyms: TYRA-300
Research Areas:
Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
Cat. No.: HY-W755252
CAS No.: 3817-11-6
Synonyms: BBN
Target:
Research Areas:
N-Butyl-N-(4-hydroxybutyl)nitrosamine is a potent mutagen that can cause high-level of mutagenesis specifically in the epithelial cells (urothelial) of the urinary bladder. N-Butyl-N-(4-hydroxybutyl)nitrosamine is used to induce bladder cancer in rodents .
Cat. No.: HY-P99899
CAS No.: 2052591-32-7
Synonyms: PR-1498487
Target:
Research Areas:
Cat. No.: HY-126566
CAS No.: 68676-88-0
Category:
Cat. No.: HY-174981
Target:
Research Areas:
LC-MF-4 is an orally active VHL-recruiting FGFR3 PROTAC degrader and hERG potassium channel inhibitor. LC-MF-4 has an IC50 of 16.6 nM against human FGFR3, exhibits inhibitory activity against hERG potassium channels, suppresses the expression of genes related to mitochondrial biogenesis and ATP synthesis, inhibits cancer cell proliferation, and shows significant antitumor activity in mice. LC-MF-4 can be used in the research of bladder cancer, urothelial carcinoma, FGFR3 Y373C mutant cancers, and FGFR3-TACC3 fusion-positive cancers .
Cat. No.: HY-147417AS
CAS No.: 2364572-10-9
Research Areas:
Vodudeutentan sodium is a deuterated endothelin B receptor (ETBR) antagonist with no activity against human type A endothelin receptor (ETA). Vodudeutentan sodium can be incorporated into a controlled systemic release delivery system and can also be selectively combined with an additional antineoplastic agent. Vodudeutentan sodium is applicable to the research of urothelial carcinoma, bladder cancer and renal cell carcinoma .
Cat. No.: HY-182747
HDAC6-IN-79 is a HDAC6 inhibitor with an IC50 of 98.40 nM, and it also exhibits inhibitory activity against other HDAC subtypes (HDAC1: 639.0 nM, HDAC2: 798.9 nM, HDAC8: 865.7 nM, HDAC4: 1187 nM). HDAC6-IN-79 induces acetylation of α-tubulin and histone H3, reduces the viability of cancer cells, activates the autophagy pathway and induces apoptosis. HDAC6-IN-79 can be used for research related to urothelial carcinoma (bladder cancer) .
Cat. No.: HY-N19113
CAS No.: 112900-04-6
Category:
Target:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
